TrialStat

TrialStat is a provider of eClinical tools designed for clinical trials, enhancing data management and operational efficiency for pharmaceutical and biotechnology companies through innovative software solutions. TrialStat Solutions Inc. is a Canadian company headquartered in Ottawa, established in 2001. It specializes in providing electronic data capture solutions for clinical trials.

In November 2008, TrialStat was acquired by Jubilant Life Sciences Limited for an undisclosed amount. The company has completed a total of 2 deals since its inception, with the most recent deal occurring on November 18, 2008. TrialStat Solutions Inc. offers a comprehensive suite of eClinical tools specifically designed for clinical trials across various therapeutic areas.

Their core product, TrialStat EDC (Electronic Data Capture), is a scalable and hosted platform that supports clinical studies from pilot stages through to Phase IV. This suite is fully integrated and includes modules for randomization (IWRS), electronic patient-reported outcomes (ePRO), medical coding, and a vendor-neutral imaging archive. By facilitating real-time data capture and management, TrialStat EDC enhances the efficiency and accuracy of study data collection, ultimately reducing operational costs. Their client base encompasses pharmaceutical, biotechnology, medical device companies, Contract Research Organizations (CROs), and data management firms, primarily in North America and Europe, reflecting the wide geographical reach of their product offerings.

TrialStat Solutions Inc. generates revenue primarily through subscription-based models for their eClinical suite, which includes the TrialStat EDC and its integrated modules. Clients engage in contracts for access to these platforms, with agreements typically structured around annual subscriptions or project-based pricing tailored to specific clinical trials. Revenue is driven by the scalability of their services, allowing clients to choose from various configurations based on their study requirements.

The company’s flagship offerings, such as the TrialStat EDC and its eConsent module, are positioned to support a range of pricing plans that accommodate diverse budgets and operational needs. This transactional structure facilitates consistent revenue generation while providing clients with the flexibility to adapt their subscription as their projects evolve. Following the acquisition by Jubilant Life Sciences Limited in November 2008, TrialStat is poised for future growth by focusing on the development of new products and enhancements to its existing eClinical suite. The company aims to expand its reach into additional markets across North America and Europe, with targeted efforts to penetrate further into the biotechnology and medical device sectors by 2025.

Recent funding will be utilized to bolster product development teams and enhance marketing efforts in these new geographic regions.